Next Generation Sequencing Market by Technology, Product Type, Application, End User

List of Tables

The Next Generation Sequencing Market was valued at USD 17.73 billion in 2023, expected to reach USD 21.38 billion in 2024, and is projected to grow at a CAGR of 23.61%, to USD 78.21 billion by 2030.

Next Generation Sequencing (NGS) represents a suite of genetic technologies that allow rapid sequencing of entire genomes or specific areas of DNA or RNA, offering significant insights into genetics and disease detection. Its necessity is anchored in its ability to provide high-throughput sequencing data efficiently and at decreasing costs, enabling advances in personalized medicine, genetic research, and even applications in agrigenomics. NGS is primarily used in research settings, clinical diagnostics, reproductive health, pharmacogenomics, and disease management. The end-use spectrum spans academia, biotechnology firms, pharmaceuticals, and healthcare facilities. Key growth factors include advancements in sequencing technology, rising prevalence of genetic disorders, and increasing investments in genomics by both public and private sectors. The surge in demand for personalized medicine and new applications in oncology and infectious disease testing are significant opportunities. To capitalize on these, businesses should focus on developing cost-effective, faster, and more accurate sequencing technologies and expand into emerging markets that are investing in genomic research infrastructures, like APAC. Nonetheless, market growth faces challenges such as high initial setup costs, ethical concerns regarding genetic data privacy, and regulatory hurdles, especially concerning clinical applications. Limitations in data interpretation and lack of skilled workforce also impede rapid adoption. Innovations should focus on AI and machine learning integration for data analysis, development of more intuitive bioinformatics tools, and improvements in sequence assembly accuracy. The market is highly dynamic, reflecting rapid technological advances and shifting public health priorities post-pandemic, necessitating agility and continued investment in R&D to remain competitive. Strategically, firms should consider partnerships with academic research institutions and expansion of service offerings to include comprehensive genomic data interpretation services, addressing a key bottleneck in NGS utility.

KEY MARKET STATISTICS
Base Year [2023]	USD 17.73 billion
Estimated Year [2024]	USD 21.38 billion
Forecast Year [2030]	USD 78.21 billion
CAGR (%)	23.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next Generation Sequencing Market

The Next Generation Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Extensive adoption of NGS technologies in clinical diagnostics due to rapid result time and faster processin
- Increased application of NGS and exponential availability of funds for oncology research
- Emerging adoption in the agriculture sector to analyze the genetic potential of plants
Market Restraints
- Lack of the computational resources and staffing to analyze and interpret clinical data
Market Opportunities
- Continuous focus on new technology development and commercialization of NGS based products
- Increased support from government and private sector for large scale sequencing technology
Market Challenges
- Ethical and privacy concerns related to next generation sequencing data protection

Porter's Five Forces: A Strategic Tool for Navigating the Next Generation Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next Generation Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next Generation Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next Generation Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next Generation Sequencing Market

A detailed market share analysis in the Next Generation Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next Generation Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next Generation Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next Generation Sequencing Market

A strategic analysis of the Next Generation Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next Generation Sequencing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Agilent Technologies, Inc., ATDBio Ltd., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., BIO3 SCIENTIFIC SDN BHD, bioMerieux S.A., BioVendor-Laboratorni medicina a.s, Cambridge Bioscience Limited, CD Genomics, CeGaT GmbH, Charles River Laboratories, Inc., DNAnexus, Inc., DNASTAR, Inc., ELEMENT BIOSCIENCES, Enzo Life Sciences, Inc., Eppendorf SE, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Fraunhofer-Gesellschaft, GENEWIZ, Genomatix, GenPath, GenScript Biotech Corporation, GRAIL, LLC, Hamilton Company, Illumina, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., iRepertoire, Inc., LabMal, Macrogen, Inc., Medigene Sdn Bhd., Merck KGaA, NanoString Technologies, Inc., Neoscience, Norgen Biotek Corp., Oxford Nanopore Technologies PLC, Pacific Biosciences of California, Inc., PathoQuest, PCR Biosystems Ltd., Perkin Elmer, Inc., Promega Corporation, PT Pandu Biosains, Qiagen N.V., Resolution Bioscience, Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next Generation Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Technology, market is studied across Targeted Sequencing & Re-Sequencing, Whole Exome Sequencing, and Whole Genome Sequencing.
Based on Product Type, market is studied across Consumables, Platforms, and Services.
Based on Application, market is studied across Agriculture, Animal science & Veterinary Research, Diagnostics, and Drug Discovery.
Based on End User, market is studied across Academic & Research Institutes, Clinical Laboratories, Contract Research Organization, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4312A385A68A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Extensive adoption of NGS technologies in clinical diagnostics due to rapid result time and faster processin
  - 5.1.1.2. Increased application of NGS and exponential availability of funds for oncology research
  - 5.1.1.3. Emerging adoption in the agriculture sector to analyze the genetic potential of plants
- 5.1.2. Restraints
  - 5.1.2.1. Lack of the computational resources and staffing to analyze and interpret clinical data
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous focus on new technology development and commercialization of NGS based products
  - 5.1.3.2. Increased support from government and private sector for large scale sequencing technology
- 5.1.4. Challenges
  - 5.1.4.1. Ethical and privacy concerns related to next generation sequencing data protection
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Next Generation Sequencing Market, by Technology

6.1. Introduction
6.2. Targeted Sequencing & Re-Sequencing
6.3. Whole Exome Sequencing
6.4. Whole Genome Sequencing

7. Next Generation Sequencing Market, by Product Type

7.1. Introduction
7.2. Consumables
7.3. Platforms
7.4. Services

8. Next Generation Sequencing Market, by Application

8.1. Introduction
8.2. Agriculture
8.3. Animal science & Veterinary Research
8.4. Diagnostics
8.5. Drug Discovery

9. Next Generation Sequencing Market, by End User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Clinical Laboratories
9.4. Contract Research Organization
9.5. Hospitals & Clinics
9.6. Pharmaceutical & Biotechnology Companies

10. Americas Next Generation Sequencing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Next Generation Sequencing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Next Generation Sequencing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. QIAGEN completes acquisition of Verogen, strengthening leadership in Human ID / Forensics with NGS technologies.
- 13.3.2. QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases.
- 13.3.3. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research.
- 13.3.4. Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation.
- 13.3.5. Complete Genomics, part of MGI, Announces Next-Generation Sequencing Platforms at ASHG Annual Meeting.
- 13.3.6. BGI Australia receives NATA certification for clinical whole exome sequencing.
- 13.3.7. ASM Announces CDC-Funded Genomic Surveillance Training Program.
- 13.3.8. The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market.
- 13.3.9. Illumina launches next-generation DNA sequencers.
- 13.3.10. Thermo Fisher Scientific Launches CE-IVD Marked Next-Generation Sequencing Instrument for Use in Clinical Labs.
- 13.3.11. Illumina and Trivitron Partner to Accelerate Disease Detection and Diagnosis for Patients in India.
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. 10x Genomics, Inc.
2. Agilent Technologies, Inc.
3. ATDBio Ltd.
4. BGI Genomics Co., Ltd.
5. Bio-Rad Laboratories, Inc.
6. BIO3 SCIENTIFIC SDN BHD
7. bioMerieux S.A.
8. BioVendor-Laboratorni medicina a.s
9. Cambridge Bioscience Limited
10. CD Genomics
11. CeGaT GmbH
12. Charles River Laboratories, Inc.
13. DNAnexus, Inc.
14. DNASTAR, Inc.
15. ELEMENT BIOSCIENCES
16. Enzo Life Sciences, Inc.
17. Eppendorf SE
18. Eurofins Scientific SE
19. F. Hoffmann-La Roche Ltd.
20. Fraunhofer-Gesellschaft
21. GENEWIZ
22. Genomatix
23. GenPath
24. GenScript Biotech Corporation
25. GRAIL, LLC
26. Hamilton Company
27. Illumina, Inc.
28. Integrated DNA Technologies, Inc.
29. Invivoscribe, Inc.
30. iRepertoire, Inc.
31. LabMal
32. Macrogen, Inc.
33. Medigene Sdn Bhd.
34. Merck KGaA
35. NanoString Technologies, Inc.
36. Neoscience
37. Norgen Biotek Corp.
38. Oxford Nanopore Technologies PLC
39. Pacific Biosciences of California, Inc.
40. PathoQuest
41. PCR Biosystems Ltd.
42. Perkin Elmer, Inc.
43. Promega Corporation
44. PT Pandu Biosains
45. Qiagen N.V.
46. Resolution Bioscience, Inc.
47. Takara Bio Inc.
48. Thermo Fisher Scientific Inc.